Nicosia, Cyprus. The Cyprus Stock Exchange council announced the admission to trading of 4,167 additional shares of iDNA Genomics Public Ltd on the Emerging Companies Market. The shares were issued following the conversion of 100 convertible bonds into shares.
Share admission and capital increase
The exchange said the conversion was carried out in accordance with Article 58 of the CSE Law. The newly admitted shares will be incorporated into the company’s existing listed share capital, increasing the total number of shares to 2,764,500.
Convertible bond balance
Following the conversion, the number of convertible bonds traded on the CSE under the code IDNAB28 will decrease to 700 bonds, the exchange said.
Start of trading date
Trading of the new shares is set to commence on March 30, 2026, when the updated quantities of the listed securities will also take effect.
What impact do you expect the share admission and bond conversion to have on trading in iDNA Genomics securities?
